TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY

Abstract

A combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and at least one additional compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody, for use in the treatment of multiple myeloma. A kit comprising tasquinimod and a package insert with instructions for using tasquinimod in combination with at least one additional compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody, to treat multiple myeloma in an individual. Tasquinimod for use in the treatment of multiple myeloma, in combination with an additional compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody.

Claims

1. A combination characterized in that it comprises tasquinimod, or a pharmaceutically acceptable salt thereof, and at least one additional compound selected from (i) a proteasome inhibitor, (ii) an immunomodulatory imide, and (iii) an antibody for use in the treatment of multiple myeloma.

2. The combination for use according to claim 1, wherein the tasquinimod, or the pharmaceutically acceptable salt thereof, and at least the additional compound are administered separately, sequentially, or simultaneously.

3. The combination for use according to claim 1 or 2, comprising (i) a proteasome inhibitor, and optionally an additional compound selected from (ii) an immunomodulatory imide, and (iii) an antibody.

4. The combination for use according to claim 1 or 2, comprising (i) an immunomodulatory imide, and optionally an additional compound selected from (ii) a proteasome inhibitor, and (iii) an antibody.

5. The combination for use in accordance with any of claims 1 to 4, comprising (i) a proteasome inhibitor, and (ii) an immunomodulatory imide, and optionally (iii) an antibody.

6. The combination for use in accordance with any of claims 1 to 5, further comprising a corticosteroid.

7. The combination for use according to claim 6, wherein the corticosteroid is selected from dexamethasone and prednisone.

8. A kit characterized in that it comprises tasquinimod and a package insert with instructions for using tasquinimod in combination with at least one additional compound selected from (i) a proteasome inhibitor, (ii) an immunomodulatory imide, and (iii) an antibody, to treat multiple myeloma in an individual.

9. The kit according to claim 8, characterized in that it further comprises at least one additional compound selected from (i) a proteasome inhibitor, (ii) an immunomodulatory imide, and (iii) an antibody.

10. Tasquinimod or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma, wherein tasquinimod or the pharmaceutically acceptable salt thereof is used in combination with at least one compound selected from (i) a proteasome inhibitor, (ii) an immunomodulatory imide, and (iii) an antibody.

11. Tasquinimod or a pharmaceutically acceptable salt thereof, for use according to claim 10, wherein the tasquinimod or the pharmaceutically acceptable salt thereof is used in combination with (i) a proteasome inhibitor, and optionally an additional compound selected from (ii) an immunomodulatory imide, and (iii) an antibody.

12. Tasquinimod or a pharmaceutically acceptable salt thereof, for use according to claim 10, wherein the tasquinimod or the pharmaceutically acceptable salt thereof is used in combination with (i) an immunomodulatory imide, and optionally an additional compound selected from (ii) a proteasome inhibitor, and (iii) an antibody.

13. Tasquinimod or a pharmaceutically acceptable salt thereof, for use in accordance with any of claims 10 to 12, wherein the tasquinimod or the pharmaceutically acceptable salt thereof is used in combination with (i) a proteasome inhibitor, and (ii) an immunomodulatory imide, and optionally (iii) an antibody.

14. Tasquinimod or a pharmaceutically acceptable salt thereof, for use in accordance with any of claims 10 to 13, wherein the combination also comprises the administration of a corticosteroid.

15. The combination for use according to any one of claims 1 to 7, or the kit according to claims 8 or 9, or tasquinimod or its pharmaceutically acceptable salt for use according to any one of claims 10 to 14, wherein (i) the proteasome inhibitor is selected from bortezomib, ixazomib, delanzomib, carfilzomib, oprozomib; and marizomib; (ii) the immunomodulatory imide is selected from thalidomide, lenalidomide and pomalidomide; and (iii) the antibody is selected from daratumumab, ixatuximab and elotuzumab.